drugset / Trial / NCT04141995
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the feasibility and safety of combining digoxin as a modulator of the hypoxia pathway in combination with FOLinic acid, 5-Fluorouracil, IRINotecan and OXaliplatin (FOLFIRINOX) in participants with resectable pancreatic cancer.
Timeline
- Start
- 2021-02-12
- Primary completion
- 2025-05-13
- Completion
- 2025-05-13
Outcome
Outcome not reported
Stopped (Enrollment): “Due to low accrual and futility”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Digoxin | Other / unclassified | 0.125 mg | Oral |
| Subject | Digoxin | Other / unclassified | 0.25 mg | Oral |
| Background | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Background | calcium leucovorin | Unknown | 400 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |